Affordable Access

Access to the full text

Recent advances in pharmacological diversification of Src family kinase inhibitors

Authors
  • Negi, Preeya1
  • Cheke, Rameshwar S.2
  • Patil, Vaishali M.1
  • 1 KIET School of Pharmacy, KIET Group of Institutions, Delhi-NCR, Ghaziabad, India , Ghaziabad (India)
  • 2 Dr. Rajendra Gode College of Pharmacy, Malkapur, Maharashtra, India , Malkapur (India)
Type
Published Article
Journal
Egyptian Journal of Medical Human Genetics
Publisher
Springer Berlin Heidelberg
Publication Date
Jun 01, 2021
Volume
22
Issue
1
Identifiers
DOI: 10.1186/s43042-021-00172-x
Source
Springer Nature
Keywords
License
Green

Abstract

BackgroundSrc kinase, a nonreceptor protein-tyrosine kinase is composed of 11 members (in human) and is involved in a wide variety of essential functions required to sustain cellular homeostasis and survival.Main body of the abstractDeregulated activity of Src family kinase is related to malignant transformation. In 2001, Food and Drug Administration approved imatinib for the treatment of chronic myeloid leukemia followed by approval of various other inhibitors from this category as effective therapeutics for cancer patients. In the past decade, Src family kinase has been investigated for the treatment of diverse pathologies in addition to cancer. In this regard, we provide a systematic evaluation of Src kinase regarding its mechanistic role in cancer and other diseases. Here we comment on preclinical and clinical success of Src kinase inhibitors in cancer followed by diabetes, hypertension, tuberculosis, and inflammation.Short conclusionStudies focusing on the diversified role of Src kinase as potential therapeutical target for the development of medicinally active agents might produce significant advances in the management of not only various types of cancer but also other diseases which are in demand for potent and safe therapeutics.

Report this publication

Statistics

Seen <100 times